abstract |
The present invention provides a peptide comprising an adenoviral (Ad) penton base epitope for a human neutralising antibody; the epitope may be a fragment from within region 50-120, 191-233 or 310-408 of Ad5 or an equivalent region within another Ad serotype, or an immunologically equivalent variant of such a fragment; particularly preferred epitopes include GGRNSIRYSELA, TRVYLVDNKSTD, QTINLDDRSHWG, HYLKVGRQNGVL, FRLGFDPVTGLV, VTGLVMPGVYTN, SNSSGSGAEENS, DHAIRGDTFATR, DSTFTQYRSWYL, RRTCPYVYKALG; as well as the use of such peptides and corresponding nucleic acid molecules in therapy and formulations comprising these molecules, optionally together with an adenoviral vector. |